Sugar control following different exercises in diabetic patients with heart disease

Phase 2

• Conditions: type 2 diabetes mellitus with coronary artery disease.; non insulin dependent diabetes mellitus

• Registration Number: IRCT2014120820239N1
• Lead Sponsor: niversity Malaya Research Grant (UMRG)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

Patients who fulfill the inclusion and exclusion criteria as listed below are recruited:
Inclusion criteria for the subjects are patients with type 2 diabetes mellitus with coronary artery disease co-morbidity manifested by one or more of these:
-Ischemic Heart Disease, but no current angina
-Post angioplasty / stenting or post coronary artery bypass surgery
-Stable pharmacological therapy
-Chronic Heart Failure New York Association (NYHA I, II and III) in the absence of congestive heart failure at the time of study

Patients with the listed criteria are excluded from the study:
-Myocardial Infarction, Cardiac arrest, symptomatic or sustained ventricular tachycardia in the previous 6 months
-Unstable heart failure, or NYHA Class IV patients
-Symptomatic or sustained ventricular tachycardia
-Current angina or baseline assessment suggesting unsatisfactory control of heart failure
-Current acute musculoskeletal event and/or neurological impairments that adversely affect exercise capacity.
-Any other symptoms that prevent the patients from exercising.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
HbA1c (glycated haemoglobin). Timepoint: 12 weeks following end of treatment. Method of measurement: Blood sample laboratory test.

Secondary Outcome Measures

Name	Time	Method
Body composition. Timepoint: 12 weeks following end of treatment. Method of measurement: bioelectrical impedance analysis machine.;Lipid profile. Timepoint: 12 weeks following end of treatment. Method of measurement: Blood sample laboratory test.;Fasting blood glucose. Timepoint: 12 weeks following end of treatment. Method of measurement: Blood sample laboratory test.;Maximum oxygen consumption (VO2max). Timepoint: 12 weeks following end of treatment. Method of measurement: cycling ergometer using Astrand or Naughton protocol.